Collection / GLP-3 40mg Pen
GLP-3 40mg Pen
GLP-3 is the catalogue name for retatrutide, a GIP, GLP-1 and glucagon receptor triple agonist. Controlled clinical research examines metabolic and body-weight endpoints for the investigational molecule.
Simulation only · No real order or payment.
GIP, GLP-1 and glucagon receptor triple agonist
Also known as: Retatrutide · LY3437943
Human trialResearch & handling
Not for human or veterinary use. Storage, handling, identity and purity require verified batch documentation. No dosing or treatment advice is provided.
At a glance
Three receptor targets
GIP, GLP-1 and glucagon receptor activity frame its metabolic research identity.
Metabolic-health research
Reviewed trials investigate body-weight endpoints in defined populations.
Clinical evidence
Trial interventions and monitored participants are distinct from a catalogue vial or pen.
Explore the study context and sources below. For laboratory research only.
Studies & context
GLP-3 is a nickname for retatrutide, studied in adults for metabolic and body-weight outcomes. It targets GLP-1, GIP and glucagon receptors: three targets, not three established benefits.
Human trialJastreboff et al. (NEJM, 2023) randomized 338 adults with obesity, or overweight plus a weight-related condition, in a 48-week phase 2 trial.
Study limitations
Receptor activity concerns metabolic signalling; measured weight change is a separate endpoint, not proof of an appetite mechanism or a PEPTIVIA product effect.
At week 48, least-squares mean body-weight change was −24.2% in the investigational 12 mg arm (starting at 2 mg), versus −2.1% with placebo; week 24 was the primary endpoint.
Study limitations
This is a specific trial arm and secondary endpoint, not expected weight loss from a purchased vial or a use recommendation.
Gastrointestinal adverse events were dose-related and mostly mild to moderate; heart-rate increases peaked at week 24 and declined thereafter.
Study limitations
Safety findings belong to the studied investigational molecule and monitored trial conditions, not PEPTIVIA’s batch.
Published research is separate from PEPTIVIA identity, content, purity, sterility and batch documentation. No source-supplier report verifies PEPTIVIA material.